Saskia de Groot1, Naomi van der Linden2, Margreet G Franken3, Hedwig M Blommestein4, Brenda Leeneman2, Ellen van Rooijen2, J J M Koos van der Hoeven5, Michel W Wouters6, Hans M Westgeest7, Carin A Uyl-de Groot8. 1. Institute of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands. Electronic address: degroot@imta.eur.nl. 2. Institute of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands. 3. Institute of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands. 4. Institute of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands; Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands. 5. Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands. 6. Dutch Institute for Clinical Auditing (DICA), Leiden, The Netherlands; Netherlands Cancer Institute, Amsterdam, The Netherlands. 7. Institute of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands; Department of Oncology, Amphia Hospital, Breda, The Netherlands. 8. Institute of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands; Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
Abstract
OBJECTIVES: The aim of this article was to provide practical guidance in setting up patient registries to facilitate real-world data collection for health care decision making. METHODS: This guidance was based on our experiences and involvement in setting up patient registries in oncology in the Netherlands. All aspects were structured according to 1) mission and goals ("the Why"), 2) stakeholders and funding ("the Who"), 3) type and content ("the What"), and 4) identification and recruitment of patients, data handling, and pharmacovigilance ("the How"). RESULTS: The mission of most patient registries is improving patient health by improving the quality of patient care; monitoring and evaluating patient care is often the primary goal ("the Why"). It is important to align the objectives of the registry and agree on a clear and functional governance structure with all stakeholders ("the Who"). There is often a trade off between reliability, validity, and specificity of data elements and feasibility of data collection ("the What"). Patient privacy should be carefully protected, and address (inter-)national and local regulations. Patient registries can reveal unique safety information, but it can be challenging to comply with pharmacovigilance guidelines ("the How"). CONCLUSIONS: It is crucial to set up an efficient patient registry that serves its aims by collecting the right data of the right patient in the right way. It can be expected that patient registries will become the new standard alongside randomized controlled trials due to their unique value.
OBJECTIVES: The aim of this article was to provide practical guidance in setting up patient registries to facilitate real-world data collection for health care decision making. METHODS: This guidance was based on our experiences and involvement in setting up patient registries in oncology in the Netherlands. All aspects were structured according to 1) mission and goals ("the Why"), 2) stakeholders and funding ("the Who"), 3) type and content ("the What"), and 4) identification and recruitment of patients, data handling, and pharmacovigilance ("the How"). RESULTS: The mission of most patient registries is improving patient health by improving the quality of patient care; monitoring and evaluating patient care is often the primary goal ("the Why"). It is important to align the objectives of the registry and agree on a clear and functional governance structure with all stakeholders ("the Who"). There is often a trade off between reliability, validity, and specificity of data elements and feasibility of data collection ("the What"). Patient privacy should be carefully protected, and address (inter-)national and local regulations. Patient registries can reveal unique safety information, but it can be challenging to comply with pharmacovigilance guidelines ("the How"). CONCLUSIONS: It is crucial to set up an efficient patient registry that serves its aims by collecting the right data of the right patient in the right way. It can be expected that patient registries will become the new standard alongside randomized controlled trials due to their unique value.
Authors: David C Dale; Audrey Anna Bolyard; Laurie A Steele; Cornelia Zeidler; Karl Welte Journal: Curr Opin Hematol Date: 2020-01 Impact factor: 3.284
Authors: Claudia Pansieri; Chiara Pandolfini; Antonio Clavenna; Imti Choonara; Maurizio Bonati Journal: Int J Environ Res Public Health Date: 2020-04-28 Impact factor: 3.390
Authors: Arthur Kavanaugh; Kim Papp; Alice B Gottlieb; Elke M G J de Jong; Soumya D Chakravarty; Shelly Kafka; Wayne Langholff; Kamyar Farahi; Bhaskar Srivastava; Jose U Scher Journal: BMC Rheumatol Date: 2018-09-29
Authors: Jan B F Hulscher; Joachim F Kuebler; Janneke M Bruggink; Mark Davenport; Stefan Scholz; Claus Petersen; Omid Madadi-Sanjani; Nagoud Schukfeh Journal: J Clin Med Date: 2022-02-21 Impact factor: 4.241
Authors: Rasa Ruseckaite; Ashika D Maharaj; Joanne Dean; Karolina Krysinska; Ilana N Ackerman; Angela L Brennan; Ljoudmila Busija; Helen Carter; Arul Earnest; Christopher B Forrest; Ian A Harris; Janet Sansoni; Susannah Ahern Journal: BMC Health Serv Res Date: 2022-03-01 Impact factor: 2.655
Authors: Yllka Kodra; Jérôme Weinbach; Manuel Posada-de-la-Paz; Alessio Coi; S Lydie Lemonnier; David van Enckevort; Marco Roos; Annika Jacobsen; Ronald Cornet; S Faisal Ahmed; Virginie Bros-Facer; Veronica Popa; Marieke Van Meel; Daniel Renault; Rainald von Gizycki; Michele Santoro; Paul Landais; Paola Torreri; Claudio Carta; Deborah Mascalzoni; Sabina Gainotti; Estrella Lopez; Anna Ambrosini; Heimo Müller; Robert Reis; Fabrizio Bianchi; Yaffa R Rubinstein; Hanns Lochmüller; Domenica Taruscio Journal: Int J Environ Res Public Health Date: 2018-08-03 Impact factor: 3.390